Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 210 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Desc)]
Φίλτρα: Συντάκτης is Athyros, Vasilios G  [Clear All Filters]
2003
Didangelos, T. P., Arsos G. A., Karamitsos D. T., Athyros V. G., & Karatzas N. D. (2003).  Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with or without autonomic neuropathy: a radionuclide ventriculography study.. Diabetes Care. 26(7), 1955-60.
2005
Athyros, V. G., Mikhailidis D. P., Papageorgiou A. A., Didangelos T. P., Peletidou A., Kleta D., et al. (2005).  Targeting vascular risk in patients with metabolic syndrome but without diabetes.. Metabolism. 54(8), 1065-74.
2006
Karagiannis, A., Mathiopoulou L., Tziomalos K., Kontotasios K., Skaperdas A., Florentin M., et al. (2006).  Dry cough as first manifestation of giant-cell arteritis.. J Am Geriatr Soc. 54(12), 1957-8.
Kakafika, A. I., Liberopoulos E. N., Karagiannis A., Athyros V. G., & Mikhailidis D. P. (2006).  Dyslipidaemia, hypercoagulability and the metabolic syndrome.. Curr Vasc Pharmacol. 4(3), 175-83.
Athyros, V. G., Mikhailidis D. P., Didangelos T. P., Giouleme O. I., Liberopoulos E. N., Karagiannis A., et al. (2006).  Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.. Curr Med Res Opin. 22(5), 873-83.
Didangelos, T. P., Arsos G. A., Karamitsos D. T., Athyros V. G., Georga S. D., & Karatzas N. D. (2006).  Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy.. J Diabetes Complications. 20(1), 1-7.
Karagiannis, A., Athyros V. G., Papageorgiou A., Tziomalos K., & Elisaf M. (2006).  Should atenolol still be recommended as first-line therapy for primary hypertension?. Hellenic J Cardiol. 47(5), 298-307.
2007
Athyros, V. G., Mikhailidis D. P., Kakafika A. I., Tziomalos K., & Karagiannis A. (2007).  Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?. Expert Opin Pharmacother. 8(5), 529-35.
Athyros, V. G., Liberopoulos E. N., Mikhailidis D. P., Papageorgiou A. A., Ganotakis E. S., Tziomalos K., et al. (2007).  Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, CHD, stroke, and peripheral arterial disease in a Mediterranean cohort.. Angiology. 58(6), 689-97.
Karagiannis, A., Mikhailidis D. P., Kakafika A. I., Tziomalos K., & Athyros V. G. (2007).  Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?. Curr Pharm Des. 13(2), 229-39.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Tziomalos K., Skaperdas A., Pagourelias E., et al. (2007).  Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients.. Lipids. 42(11), 999-1009.
Athyros, V. G., Tziomalos K., Mikhailidis D. P., Pagourelias E. D., Kakafika A. I., Skaperdas A., et al. (2007).  Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. Expert Opin Pharmacother. 8(14), 2267-77.
Athyros, V. G., Mikhailidis D. P., Liberopoulos E. N., Kakafika A. I., Karagiannis A., Papageorgiou A. A., et al. (2007).  Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with CHD and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study.. Nephrol Dial Transplant. 22(1), 118-27.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2007).  Endothelial function, arterial stiffness and lipid lowering drugs.. Expert Opin Ther Targets. 11(9), 1143-60.
Athyros, V. G., Mikhailidis D. P., Kakafika A. I., Karagiannis A., Hatzitolios A., Tziomalos K., et al. (2007).  Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels.. Curr Drug Targets. 8(3), 483-8.
Kakafika, A. I., Mikhailidis D. P., Wierzbicki A. S., Karagiannis A., & Athyros V. G. (2007).  PCI and stable coronary heart disease--COURAGE to change our minds?. Curr Vasc Pharmacol. 5(3), 173-4.
Karagiannis, A., Mikhailidis D. P., Athyros V. G., & Harsoulis F. (2007).  Pheochromocytoma: an update on genetics and management.. Endocr Relat Cancer. 14(4), 935-56.
Athyros, V. G., Ganotakis E. S., Elisaf M. S., Liberopoulos E. N., Goudevenos I. A., & Karagiannis A. (2007).  Prevalence of vascular disease in metabolic syndrome using three proposed definitions.. Int J Cardiol. 117(2), 204-10.
Kakafika, A. I., Mikhailidis D. P., Karagiannis A., & Athyros V. G. (2007).  The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.. J Clin Pharmacol. 47(5), 642-52.
Karagiannis, A., Mikhailidis D. P., Athyros V. G., Kakafika A. I., Tziomalos K., Liberopoulos E. N., et al. (2007).  The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. Expert Opin Ther Targets. 11(2), 191-205.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Pagourelias E. D., Savvatianos S. D., Elisaf M., et al. (2007).  Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients.. Open Cardiovasc Med J. 1, 8-14.
Athyros, V. G., Kakafika A., Karagiannis A., & Mikhailidis D. P. (2007).  Statins and regression of coronary atherosclerosis.. JAMA. 297(20), 2197; author reply 2197.
Athyros, V. G., Karagiannis A., Kakafika A., Elisaf M., & Mikhailidis D. P. (2007).  Statins and renal function. Is the compound and dose making a difference?. Nephrol Dial Transplant. 22(3), 963-4; author reply 964.
Paraskevas, K. I., Athyros V. G., Briana D. D., Kakafika A. I., Karagiannis A., & Mikhailidis D. P. (2007).  Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures.. Curr Drug Targets. 8(8), 942-51.
2008
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster?. Expert Opin Investig Drugs. 17(7), 969-72.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές